close

Cytomedix, Inc., a biotechnology company, engages in the development, sale, and licensing of regenerative biological therapies for wound care, inflammation, and angiogenesis primarily in the United States. The company provides the AutoloGel System, a device for the production of platelet rich plasma gel that is derived from the patient's own blood. Its products include the AutoloGel System Centrifuge II, the AutoloGel wound dressing Kits, and AutoloGel reagents kits. These products are used for the treatment of exuding wounds, such as leg ulcers, pressure ulcers, and diabetic ulcers, as well as for the management of mechanically or surgically debrided wounds. The company also focuses on developing CT 112, which is an anti-inflammatory peptide. It markets its products primarily to health care providers, and licenses its patents to surgical medical device suppliers. Cytomedix, Inc. has licensing agreements with DePuy Spine, Inc.; Medtronic, Inc.; Harvest Technologies, Inc.; Perfusion Partners and Associates, Inc.; COBE Cardiovascular, Inc.; SafeBlood Technologies, Inc.; Biomet Biologics, Inc.; CellMedix, Inc.; and Smith and Nephew, Inc. The company was formerly known as Autologous Wound Therapy, Inc. and changed its name to Cytomedix, Inc. in 2000. Cytomedix, Inc. was founded in 1987 and is headquartered in Rockville, Maryland.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	0.00
Volume	0
Volume Avg	275436
52 Week High	1.75
52 Week Low	0.41
PE	N/A
PE (group average)	39
EPS Year	0.00
EPS change Q/Q	-266.67%
EPS change Q/Q Yr ago	-266.67%
EPS change Q/Q next Q est	100%
EPS change Y/Y	-35.29%
REV change Q/Q	450%
REV change Q/Q Yr ago	83.33%
EPS next Q est	0.00
EPS next Y est	0.00
Divident Annual	0.00
Dividend Yield	0%